Compare HubSpot Inc (HUBS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Sanofi SA — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 8.2× HubSpot Inc's market cap, and Sanofi SA pays a 6.01% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Sanofi SA for 94 Days on average.
| HUBS | SNY | |
|---|---|---|
Market Cap | $11.56B | $95.18B |
Volume | 1,891,287 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $494.58 | $52.34 |
52-Week Low | $170.39 | $39.51 |
Typical Hold Time | 78 Days | 94 Days |
Enterprise Value | $10.46B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.84, up 5.23% over the past day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, improving profitability, and positive cash flow trends, supported by an AI-focused strategy unveiled at its recent Analyst Day. Analyst consensus is bullish with a $243.65 price target, though high valuation multiples and competitive pressures remain considerations.
The outlook for HUBS is positive, driven by AI integration, margin expansion targets, and consistent revenue growth. Key risks include elevated valuation metrics, potential AI-driven demand headwinds, and insider selling activity. The stock presents a growth opportunity but requires monitoring of execution against ambitious targets and competitive dynamics in the CRM software space.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
